Past News Releases

Stryker hip lawsuits (http://www.strykerhiprecallclaims.com/) filed in the wake of the 2012 recall for Rejuvenate and ABG II Modular-Neck Hip Stems continue to move forward in courts throughout the U.S. According to an Order dated April 22, 2014, the judge overseeing federally-filed Stryker hip recall claims in the U.S. District Court, District of Minnesota has directed plaintiffs’ attorneys to coordinate with a state litigation underway in New Jersey’s Bergen County Superior Court, in order to obtain information about the proceeding’s Early Mediation Program. Specifically, the attorneys are to “explore what, if anything, can be learned from the New Jersey court’s Early Mediation Program that may be applied usefully in this MDL.” (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, No. 244)

“Our Firm is representing numerous Stryker hip lawsuit clients whose cases are pending in the New Jersey litigation and we have been actively involved with the Early Mediation Program.” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who have suffered serious complications, allegedly related to the Stryker hip recall for Rejuvenate and ABG II hip stems.

Stryker Hip Recall Litigation
According to court documents, nearly 1,700 Stryker hip lawsuits have been filed in U.S. courts on behalf of individuals who were allegedly harmed by Rejuvenate hip stems. These include at least 950 that are pending in the New Jersey litigation, where early mediation efforts have already resulted in several Stryker hip lawsuit settlements. All of claims allege that the Rejuvenate and ABG II hip stems were defectively designed and manufactured, and caused recipients to suffer osteolysis, tissue necrosis, adverse local tissue reactions, and other debilitatingcomplications. The lawsuits further allege that many affected by the Stryker hip recall are suffering from permanent pain and disability, even after they underwent risky surgical procedures to remove and replace their hip implants. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296)

In addition to the Stryker hip lawsuits filed in New Jersey, almost 700 complaints involving similar allegations are pending in multidistrict litigation underway in the District of Minnesota.

The Stryker hip recall was announced in July 2012, after post-market data indicated that the Rejuvenate and ABG II hip stems were associated with high rates of fretting and corrosion at the modular-neck junction. According to Stryker, patients fitted with these components are at risk for pain, swelling and adverse local tissue reactions. The company has recommended all patients who received a Rejuvenate or ABG II hip stem undergo blood and imaging tests to ensure their device is functioning properly, even if they have not experienced any symptoms related to a failing hip implant.*

Individuals who were allegedly harmed by Rejuvenate and ABG II hip stems may be entitled to file their own Stryker hip lawsuit. To learn more about the Stryker hip recall, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.

*literature.ortho.stryker.com/files/REJUV_COM_23.pdf

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092